Minimum PDDI (Potential Drug-Drug Interaction) Information Ontology

IRI:
http://purl.obolibrary.org/obo/mpio.owl
Version IRI:
http://purl.obolibrary.org/obo/mpio/release/2019-01-30/mpio.owl
Current version:
release version 2019-01-30
Authors:
Maria Herrero-Zazo
Mathias Brochhausen
Contributors:
Richard D. Boyce
Sarah Bost
Imported Ontologies:
http://purl.obolibrary.org/obo/iao/2015-02-23/ontology-metadata.owl (visualise it with LODE)
Other visualisation:
Ontology source

Table of Content

  1. Classes
  2. Object Properties
  3. Annotation Properties
  4. Namespace Declarations

Classes

biological replicate rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000198

has super-classes
reference subject rolec
has sub-classes
cohort rolec

biological_processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/GO_0008150

has sub-classes
drug-drug interactionc, drug-drug interaction effectc

clinical consequences informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000002

has super-classes
i a o 0000030
is aboutop some clinical historyc
has sub-classes
information about clinical consequences suspected to be the result of a drug-drug interactionc

clinical drug rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DRON_00000001

Authors:
William Hogan

clinical findingc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000014

has super-classes
i a o 0000027
has sub-classes
clinical historyc

clinical historyc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OGMS_0000015

has super-classes
clinical findingc

clinically relevant DDI effectc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DINTO_000027

has super-classes
drug-drug interaction effectc

cohort rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000252

has super-classes
biological replicate rolec

collection of organismsc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/PCO_0000000

countc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000032

has super-classes
measurement datumc

countingc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000033

has super-classes
planned processc

DDI mechanismc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DINTO_000003

directive information entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000033

has super-classes
i a o 0000030
has sub-classes
plan specificationc

drug co-administrationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000021

An instance of this occurs when at least two or more drugs are taken in a specific time interval and the individual time interval for each drug administration overlaps with the other drug's or drugs' time interval(s). (SG1)
has super-classes
planned processc
has participantop some material entityc and (bearer ofop some clinical drug rolec)

drug concept set identifierc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000128

Term and definition provided by Richard D. Boyce.
has super-classes
i a o 0000030

drug identifierc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/APOLLO_SV_00000461

has super-classes
i a o 0000030

drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000020

A clinically meaningful alteration in the exposure and/or response to a drug (object drug) that has occurred as a result of the co-administration of another drug (precipitant drug)Oates JA. Chapter 5. Goodman and Gilman 11th ed (2006):117–36; Hines. Response can refer to either precipitating an adverse event or altering the therapeutic effect of the object drug. Although some DDIs may be used for therapeutic benefit, this paper focuses on those with adverse clinical consequences. (based on the 2013 DDI conference series) / has participant some mechanism.
has super-classes
biological_processc
has occurrent partop some drug co-administrationc

drug-drug interaction effectc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000125

is equivalent to
process is result ofop some drug-drug interactionc
has super-classes
biological_processc
has sub-classes
clinically relevant DDI effectc

evidence information content entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000053

has super-classes
i a o 0000030

frequency of exposure informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000007

has super-classes
i a o 0000030
i a o 0000030 and (has partop some countc and (is_specified_output_ofop some countingc and (has_specified_inputop some organismc and (participates inop some drug-drug interactionc) and (is member ofop some collection of organismsc and (bearer ofop some cohort rolec))))) and (has partop some countc and (is_specified_output_ofop some countingc and (has_specified_inputop some organismc and (is member ofop some collection of organismsc and (bearer ofop some cohort rolec)))))

frequency of harm informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000006

has super-classes
i a o 0000030
i a o 0000030 and (has partop some countc and (is_specified_output_ofop some countingc and (has_specified_inputop some organismc and (participates inop some clinically relevant DDI effectc) and (is member ofop some collection of organismsc and (bearer ofop some cohort rolec))))) and (has partop some countc and (is_specified_output_ofop some countingc and (has_specified_inputop some organismc and (is member ofop some collection of organismsc and (bearer ofop some cohort rolec)))))

information about clinical consequences suspected to be the result of a drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000003

has super-classes
clinical consequences informationc
is aboutop some drug-drug interaction effectc
is aboutop some clinically relevant DDI effectc

material entityc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000040

is defined by
http://purl.obolibrary.org/obo/bfo.owl

measurement datumc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000109

has super-classes
i a o 0000027
has sub-classes
countc

mechanism of interaction informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000005

has super-classes
i a o 0000030
is aboutop some DDI mechanismc

medical context informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000000

has super-classes
i a o 0000030

Obsolete Classc back to ToC or Class ToC

IRI: http://www.geneontology.org/formats/oboInOwl#ObsoleteClass

has sub-classes
obsolete_drug-drug interaction effectc, severity informationc

obsolete_drug-drug interaction effectc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000030

has super-classes
Obsolete Classc

operational classification statementc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000111

has super-classes
i a o 0000030

organismc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0100026

participant under investigation rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000097

has sub-classes
reference subject rolec

plan specificationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000104

2/3/2009 Comment from OBI review. Action specification not well enough specified. Conditional specification not well enough specified. Question whether all plan specifications have objective specifications. Request that IAO either clarify these or change definitions not to use them
has super-classes
directive information entityc
has sub-classes
recommended action for potential drug-drug interactionc

planned processc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000011

has sub-classes
countingc, drug co-administrationc

potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/DIDEO_00000000

has super-classes
i a o 0000030
has partop some drug identifierc

recommended action for potential drug-drug interactionc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000008

has super-classes
plan specificationc
(is aboutop some potential drug-drug interactionc) and (is aboutop some evidence information content entityc)

reference subject rolec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000220

has super-classes
participant under investigation rolec
has sub-classes
biological replicate rolec

seriousness informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000009

An event is serious when the patient outcome is: Death, Life-threatening Hospitalization (initial or prolonged), disability or permanent damage, congenital anomaly/birth Defect, required intervention to prevent permanent impairment or damage, in involved other important medical events. Source: U.S. Food and Drug Administration. “What is a Serious Adverse Event?” https://urldefense.proofpoint.com/v2/url?u=http-3A__www.fda.gov_Safety_MedWatch_HowToReport_ucm053087.htm&d=DwIGaQ&c=27AKQ-AFTMvLXtgZ7shZqsfSXu-Fwzpqk4BoASshREk&r=_AhKSLG63uT9j7OK4dL0o2DAco1lYASNsYomMJX92ng&m=akNLTN3AxpBiAQmCa5kBvV98eEf8Pl2M-D5MBaU5ANI&s=i_7V5GfnXHZV_wJ4fPZCRVM66e0ZhKlG86F0WWSbxSY&e= (accessed August 19, 2016)
has super-classes
i a o 0000030

severity informationc back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000010

Severity is a term that is too similar to seriousness possibly causing confusion when communicating with clinicians. Moreover, seriousness (like the related term criticality) describes a POTENTIAL impact, whereas severity characterizes a reaction that has been realized in an individual. Since MPIO focuses on potential drug-drug interactions, it cannot include an attribute (severity) that is describing a realized reaction because you are then no longer in the realm of the potential. Finally, the W3C community workgroup that worked on the minimum information model for potential drug-drug interactions greatly preferred the use of an operational classification of risk to a severity rating. Hence, it was obsoleted as a failed exploratory term for the MPIO domain.
has super-classes
Obsolete Classc

suspected drug-drug interaction evidencec back to ToC or Class ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000004

has super-classes
i a o 0000030

Object Properties

bearer ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000053

has super-properties
top object property

has memberop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002351

has super-properties
top object property

has occurrent partop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000117

is defined by
http://purl.obolibrary.org/obo/bfo.owl
has super-properties
top object property

has partop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000051

has super-properties
top object property

has participantop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000057

has super-properties
top object property

has_specified_inputop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000293

has super-properties
top object property

immediately preceded byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0002087

X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y)
has super-properties
preceded byop
has sub-properties
process is result ofop

is aboutop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000136

has super-properties
top object property

is member ofop back to ToC or Object Property ToC

IRI: http://semanticscience.org/resource/SIO_000095

is defined by
http://semanticscience.org/ontology/sio.owl
has super-properties
top object property

is_specified_output_ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_0000312

has super-properties
top object property

participates inop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0000056

has super-properties
top object property

preceded byop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000062

has super-properties
top object property
has sub-properties
immediately preceded byop

process is result ofop back to ToC or Object Property ToC

IRI: http://purl.obolibrary.org/obo/OBI_1110060

has super-properties
immediately preceded byop

Annotation Properties

BFO CLIF specification labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000180

BFO OWL specification labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/BFO_0000179

contributorap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/contributor

coverageap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/coverage

creatorap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/creator

dateap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/date

Definitionap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org#Definition

descriptionap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/description

descriptionap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/terms/description

formatap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/format

identifierap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/identifier

imported fromap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/IAO_0000412

languageap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/language

memberap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/member

MPIO user-centered definitionap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/MPIO_0000001

publisherap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/publisher

relationap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/relation

rightsap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/rights

Sourceap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/source

subjectap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/subject

Synonymap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo#Synonym

temporal interpretationap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/RO_0001900

titleap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/title

typeap back to ToC or Annotation Property ToC

IRI: http://purl.org/dc/elements/1.1/type

Unique Apollo Labelap back to ToC or Annotation Property ToC

IRI: http://purl.obolibrary.org/obo/apollo_sv.owl/APOLLO_SV_0000040

Namespace Declarations back to ToC

default namespace
http://purl.obolibrary.org/obo/mpio.owl#
2015-02-23
http://purl.obolibrary.org/obo/iao/2015-02-23/
2019-01-30
http://purl.obolibrary.org/obo/mpio/release/2019-01-30/
apollo_sv
http://purl.obolibrary.org/obo/apollo_sv.owl/
axiom
http://purl.obolibrary.org/obo/bfo/axiom/
dc
http://purl.org/dc/elements/1.1/
obo
http://purl.obolibrary.org/obo/
obo2
http://purl.obolibrary.org/obo#
oboinowl
http://www.geneontology.org/formats/oboInOwl#
ontology
http://semanticscience.org/ontology/
owl
http://www.w3.org/2002/07/owl#
purl
http://purl.obolibrary.org#
rdf
http://www.w3.org/1999/02/22-rdf-syntax-ns#
rdfs
http://www.w3.org/2000/01/rdf-schema#
resource
http://semanticscience.org/resource/
terms
http://purl.org/dc/terms/
xsd
http://www.w3.org/2001/XMLSchema#

This HTML document was obtained by processing the OWL ontology source code through LODE, Live OWL Documentation Environment, developed by Silvio Peroni.